Back to "The post- and pre-treatment difference w..."
Claim
Strong Support
quantitative
Analysis v4

Former smokers who took 120 micromoles of sulforaphane daily for 12 months showed a 46% reduction in high-density Ki-67 staining in bronchial tissue, while those who took a placebo showed a 99%...

61
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Sulforaphane turns on a cellular cleanup system that removes harmful chemicals from tobacco smoke. This stops the airway cells from getting damaged and dividing too quickly, which reduces the number of cells showing signs of rapid growth.

Most probable mechanism

In Simple Terms

Sulforaphane enters cells in the airways and turns on a defense system that cleans up harmful chemicals and repairs damaged DNA. This stops the cells from dividing too fast, which reduces the number of cells showing signs of rapid growth.

Causal chain
1

Sulforaphane is absorbed from the digestive tract and reaches bronchial epithelial cells in the airways

Supported by evidence
which leads to
2

Sulforaphane binds to and modifies specific cysteine residues on the Keap1 protein, preventing it from tagging Nrf2 for degradation

Supported by evidence
which leads to
3

Stabilized Nrf2 moves into the cell nucleus and binds to antioxidant response elements in DNA, activating transcription of detoxification and antioxidant genes

Supported by evidence
which leads to
4

Increased expression of detoxification enzymes reduces levels of reactive oxygen species and DNA damage caused by tobacco carcinogens

Supported by evidence
which leads to
5

Reduced DNA damage decreases activation of proliferation signals in bronchial epithelial cells, leading to lower expression of the Ki-67 protein

Verified by multiple studies

Evidence from Studies

Supporting (1)

61

Community contributions welcome

61

Abstract 749: Randomized placebo-controlled phase II clinical trial on oral supplementation of sulforaphane for 12 months that reduced bronchial Ki-67 index in former smokers at high risk for lung cancer

Randomized Controlled Trial
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Abstract 749: Randomized placebo-controlled phase II clinical trial on oral supplementation of sulforaphane for 12 months that reduced bronchial Ki-67 index in former smokers at high risk for lung cancer

Score: 61
DOI: 10.1158/1538-7445.am2024-749

Similar Assertions

Taking 120 micromoles of sulforaphane daily for one year reduced the Ki-67 proliferation index by 24% in bronchial tissue of former smokers with a 30 pack-year smoking history.

61
0
86%

Higher adherence to sulforaphane supplements is linked to a measurable decrease in the Ki-67 marker in bronchial tissue, which indicates reduced cell proliferation.

61
0
77%

Taking 120 micromoles of sulforaphane daily for a year does not change levels of Caspase-3 or TUNEL markers in the bronchial tissue of former smokers.

61
0
72%